Heartflow, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Piper Sandler maintained an Overweight rating on HeartFlow with a $64 price target, suggesting a 25.4% upside from the Oct 19 close. The firm cited HeartFlow's strong market position, growth potential, and durable competitive moat in non-invasive coronary artery disease detection.
Heartflow, Inc. (Nasdaq: HTFL) will report Q3 2026 earnings on Nov. 12, with a conference call at 4:30 p.m. ET. The company's AI technology for diagnosing coronary artery disease is used by 1,800 institutions globally and supported by 625 peer-reviewed studies. Heartflow's solutions are validated against invasive gold standards and improve patient outcomes.
Farquhar John C.M. (Chief Executive Officer) sold 38,900 shares of Heartflow, Inc. (HTFL) at $49.57 ($1.93M total) on 2026-10-12 under a Rule 10b5-1 trading plan.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning HTFL (Heartflow, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent HTFL coverage spans insider activity, financial news and market movers.
In the last 30 days, HTFL insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($1.9M). The most active reporter was Farquhar John C.M., Chief Executive Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Piper Sandler maintained an Overweight rating on HeartFlow with a $64 price target, suggesting a 25.4% upside from the Oct 19 close. The firm cited HeartFlow's strong market position, growth potential, and durable competitive moat in non-invasive coronary artery disease detection.
The earnings announcement will likely generate short‑term volatility as investors position ahead of the results.
The insider sale may signal confidence concerns, likely creating modest downward pressure on HTFL.
Revenue surge may offset loss concerns, supporting further upside.
Insider sale may signal reduced confidence or portfolio rebalancing, potentially pressuring HTFL price.
AlphAI scores every news story that mentions HTFL with an AI model for sentiment and relevance, and aggregates insider trades from Heartflow, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Piper Sandler maintained an Overweight rating on HeartFlow with a $64 price target, suggesting a 25.4% upside from the Oct 19 close. The firm cited HeartFlow's strong market position, growth potential, and durable competitive moat in non-invasive coronary artery disease detection.
2 min readHeartflow, Inc. (Nasdaq: HTFL) will report Q3 2026 earnings on Nov. 12, with a conference call at 4:30 p.m. ET. The company's AI technology for diagnosing coronary artery disease is used by 1,800 institutions globally and supported by 625 peer-reviewed studies. Heartflow's solutions are validated against invasive gold standards and improve patient outcomes.
2 min readFarquhar John C.M. (Chief Executive Officer) sold 38,900 shares of Heartflow, Inc. (HTFL) at $49.57 ($1.93M total) on 2026-10-12 under a Rule 10b5-1 trading plan.
1 min readVaxcyte (PCVX) +31% on positive Phase 3 trial data, $500M stock offering. InfuSystem (INFU) +2% with Q2 revenue $36.9M, FY26 growth 6-8%. Illumina (ILMN) +7% with Q2 revenue $1.59B, FY26 guidance $4.6B-$4.64B. Charles River (CRL) +7% with Q2 revenue $1B, FY26 EPS up $0.25. HeartFlow (HTFL) +5% with Q2 revenue $64.1M, net loss $15.7M.
3 min readRogers Campbell (Chief Medical Officer) sold 19,682 shares of Heartflow, Inc. (HTFL) at $50.15 ($0.99M total) on 2026-09-18 under a Rule 10b5-1 trading plan.
1 min readSeveral biotech stocks reached 52-week highs on September 18, 2026. Vogenx (VOGX) shares surged to $38.41, driven by positive clinical trial results. HeartSciences (HSCS) rose 7% to $5.21, while HeartFlow (HTFL) increased 2% to $52.22. Freenome (FRNM) gained 5% to $17.25, and Halozyme (HALO) hit $112.66 after announcing a $1.3B offering.
4 min readHeartFlow CFO Vikram Verghese sold 24,345 shares worth $1.23M in two transactions, under a 10b5-1 plan, with shares trading near 52-week high. HeartFlow reported Q2 2026 revenue of $64.1M, up 48% YoY, and narrowed loss. Stifel raised its price target to $45, maintaining a Buy rating.
1 min readVerghese Vikram (Chief Financial Officer) sold 24,345 shares of Heartflow, Inc. (HTFL) at an average of $50.55 ($50.11–$50.75, $1.23M total) across 2 trades over 2026-09-17 to 2026-09-18 under a Rule 10b5-1 trading plan.
1 min readHeartFlow CFO Vikram Verghese sold $1.75M in shares from September 11-15, 2026, under a 10b5-1 plan. Shares sold at $50.012-$50.2381 each. HeartFlow's stock is near its 52-week high, up 130% in six months. The company reported 43% revenue growth but remains unprofitable. Q2 2026 revenue was $64.1M, beating estimates. Stifel raised its price target to $45 with a Buy rating.
1 min readVerghese Vikram (Chief Financial Officer) sold 34,975 shares of Heartflow, Inc. (HTFL) at an average of $50.08 ($50.01–$50.24, $1.75M total) across 3 trades over 2026-09-11 to 2026-09-15 under a Rule 10b5-1 trading plan.
1 min read
